The rapid global rise in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has transformed the management of type 2 diabetes and obesity. Medications such as semaglutide, liraglutide, dulaglutide, and tirzepatide are now widely prescribed not only for glycemic control but also for their remarkable effects on weight loss and cardiometabolic risk reduction. While clinicians and patients are increasingly familiar with common side effects like nausea, vomiting, diarrhea, and delayed gastric emptying, emerging evidence suggests that GLP-1 RAs may carry lesser-known risks—particularly the potential development of micronutrient deficiencies, including iron deficiency anemia (IDA).

Understanding GLP-1 Receptor Agonists

GLP-1 receptor agonists mimic the action of endogenous GLP-1, a hormone released from the gut in response to food intake. These drugs exert their therapeutic effects through several mechanisms:

• Enhancing glucose-dependent insulin secretion

• Suppressing glucagon release

• Slowing gastric emptying

• Increasing satiety and reducing appetite

Together, these actions improve glycemic control and promote sustained weight loss. However, the same mechanisms that make GLP-1 RAs effective may also interfere with normal nutrient intake and absorption.

Iron Deficiency Anemia: An Overview

Iron deficiency anemia is the most common form of anemia worldwide. It occurs when iron stores are insufficient to support normal red blood cell production, leading to reduced hemoglobin levels and impaired oxygen delivery to tissues. Symptoms often include:

• Fatigue and weakness

• Shortness of breath

• Dizziness

• Pale skin

• Reduced exercise tolerance

IDA is particularly concerning in populations already at risk, such as menstruating women, older adults, individuals with gastrointestinal disorders, and patients with chronic disease.

How GLP-1 RAs May Contribute to Iron Deficiency

Although GLP-1 receptor agonists are not traditionally classified as drugs that cause anemia, several plausible mechanisms suggest they may increase the risk of iron deficiency over time.

1. Reduced Caloric and Nutrient Intake

One of the hallmark effects of GLP-1 RAs is appetite suppression. Many patients experience a significant reduction in overall food intake, which may inadvertently lead to insufficient consumption of iron-rich foods such as red meat, legumes, leafy greens, and fortified grains. Over time, chronic caloric restriction without careful dietary planning can result in depleted iron stores.

2. Gastrointestinal Side Effects

Nausea, vomiting, early satiety, and bloating are common, particularly during dose escalation. These symptoms can discourage regular eating patterns and further reduce micronutrient intake. In some patients, persistent gastrointestinal discomfort may lead to meal skipping or avoidance of certain foods that are harder to digest but rich in iron.

3. Delayed Gastric Emptying and Absorption Issues

GLP-1 RAs slow gastric emptying, which may affect the bioavailability and absorption of certain nutrients, including iron. Adequate gastric acid is necessary for the conversion of dietary iron into its absorbable form. Alterations in gastric motility and acidity could theoretically impair iron absorption, especially non-heme iron from plant-based sources.

4. Weight Loss–Associated Nutrient Depletion

Rapid or significant weight loss itself has been associated with micronutrient deficiencies. Similar to what is observed after bariatric surgery—though typically to a lesser extent—patients on GLP-1 therapy may experience gradual depletion of iron, vitamin B12, folate, and other essential nutrients if supplementation and monitoring are not addressed.

Emerging Clinical Evidence

While large-scale randomized trials of GLP-1 RAs have not consistently reported anemia as a primary adverse outcome, real-world data and case reports are beginning to draw attention to this potential issue. Some clinicians have observed declining ferritin and hemoglobin levels in patients on long-term GLP-1 therapy, particularly among those with baseline marginal iron stores.

Importantly, these findings do not suggest that GLP-1 RAs directly cause anemia in all users. Rather, they highlight a possible association in susceptible individuals, especially when therapy is prolonged and dietary intake is significantly reduced.

Who Is Most at Risk?

Certain populations may be more vulnerable to developing iron deficiency while using GLP-1 receptor agonists:

• Premenopausal women with menstrual blood loss

• Older adults with reduced nutrient absorption

• Patients with pre-existing gastrointestinal disorders

• Individuals following restrictive or plant-based diets

• Patients with a history of anemia or low ferritin levels

In these groups, even modest reductions in iron intake or absorption may have clinically significant consequences.

Clinical Implications and Monitoring Strategies

As GLP-1 RAs become a mainstay of metabolic therapy, clinicians should adopt a more holistic approach to patient monitoring. This includes:

• Baseline assessment of iron status in high-risk patients

• Periodic monitoring of hemoglobin, ferritin, and transferrin saturation during long-term therapy

• Nutritional counseling focused on adequate protein and micronutrient intake

• Consideration of iron supplementation when clinically indicated

Early identification of iron deficiency allows for timely intervention and prevents progression to symptomatic anemia.

Patient Awareness and Education

Patients using GLP-1 receptor agonists should be educated about the importance of balanced nutrition, even when appetite is reduced. Recognizing symptoms such as persistent fatigue or weakness and reporting them promptly can facilitate early evaluation and management.

Conclusion

GLP-1 receptor agonists represent a major advancement in the treatment of diabetes and obesity, offering substantial benefits for metabolic health and cardiovascular risk reduction. However, as their use continues to expand, awareness of less obvious adverse effects—such as potential micronutrient deficiencies and iron deficiency anemia—becomes increasingly important.

While anemia is not a common or inevitable side effect of GLP-1 therapy, it may emerge in vulnerable individuals due to reduced intake, gastrointestinal effects, and altered absorption. Thoughtful patient selection, routine monitoring, and proactive nutritional support can help maximize the benefits of these powerful medications while minimizing unintended risks.